SELUTION SLR
Commercial- Indications
- Peripheral artery disease, Coronary artery disease
Company intelligence / Profile preview
MedAlliance
Nyon, Vaud, Switzerlandmedalliance.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Commercial
01
Overview
MedAlliance developed the SELUTION SLR™ sirolimus-eluting balloon platform for coronary and peripheral artery disease. The technology uses biodegradable polymer MicroReservoirs to provide controlled, sustained release of sirolimus for up to 90 days. Clinical programs have led to regulatory approvals including CE Mark; the company has an extensive clinical study program supporting global commercialization.
- Therapeutic areas
- Cardiovascular
- Modalities
- DeviceDrug-device combination productSmall molecule
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
1 asset03
Partnerships
Cordis
Beyond the preview
Go deeper on MedAlliance.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MedAlliance.